Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Investors sentiment decreased to 1.42 in Q3 2019. Its down 0.15, from 1.57 in 2019Q2. It fall, as 19 investors sold Sangamo Therapeutics, Inc. shares while 31 reduced holdings. 23 funds opened positions while 48 raised stakes. 74.01 million shares or 1.20% more from 73.13 million shares in 2019Q2 were reported.
Renaissance Technology Ltd Llc has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Mirae Asset Invs Limited reported 32,497 shares. Bankshares Of Montreal Can, Ontario – Canada-based fund reported 25,881 shares. Sector Gamma As holds 251,698 shares or 0.38% of its portfolio. Rhenman Partners Asset Management accumulated 734,811 shares. New York State Common Retirement Fund reported 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Granahan Investment Incorporated Ma accumulated 0.05% or 101,619 shares. Creative Planning owns 37,829 shares for 0% of their portfolio. Proshare Limited Liability Corporation stated it has 44,397 shares. Dupont Cap Mngmt Corp reported 31,844 shares. State Board Of Administration Of Florida Retirement Sys stated it has 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Janney Montgomery Scott Ltd Llc has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). 5,176 were reported by Us National Bank & Trust De. Whittier Trust invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Ws Management Lllp reported 0.07% stake.

The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a huge mover today! The stock decreased 4.58% or $0.41 during the last trading session, reaching $8.64. About 3.12M shares traded or 132.71% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has declined 2.26% since December 11, 2018 and is downtrending. It has underperformed by 2.26% the S&P500.
The move comes after 6 months negative chart setup for the $1000.00 million company. It was reported on Dec, 11 by Barchart.com. We have $8.12 PT which if reached, will make NASDAQ:SGMO worth $60.00 million less.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.30 EPS, down 66.67 % or $0.12 from last year’s $-0.18 per share. After $-0.24 actual EPS reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 25.00 % negative EPS growth.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Nasdaq.com which released: “Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session – Nasdaq” on December 04, 2019, also Nasdaq.com with their article: “Amazon Partners National Football League For Player Health, Safety – Nasdaq” published on December 06, 2019, Finance.Yahoo.com published: “The Gene Therapy Names Moving On The Audentes Buyout Deal – Yahoo Finance” on December 03, 2019. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Nasdaq.com and their article: “Notable Tuesday Option Activity: EW, ORLY, JPM – Nasdaq” published on December 10, 2019 as well as Fool.com‘s news article titled: “Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? – The Motley Fool” with publication date: November 26, 2019.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1000.00 million. The company??s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link